Pomerantz files securities class action against Nektar Therapeutics over REZOLVE-AA trial disclosures

Reuters03-12

Pomerantz files securities class action against Nektar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> over REZOLVE-AA trial disclosures

Pomerantz LLP said a securities class action has been filed against Nektar and certain officers in the U.S. District Court for the Northern District of California under docket 26-cv-01951. The suit seeks damages for investors who bought or acquired Nektar securities between Feb. 26, 2025 and Dec. 15, 2025, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The complaint alleges the company made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial. Nektar reported on Dec. 16, 2025 that the REZOLVE-AA trial missed statistical significance, citing four ineligible patients. Following that disclosure, the stock fell 8% to close at $49.16 on Dec. 16, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603121000PR_NEWS_USPR_____DC07181) on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618137403?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618137403","market":"nz","top_or_hot":-1,"title":"Pomerantz files securities class action against Nektar Therapeutics over REZOLVE-AA trial disclosures","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pomerantz files securities class action against Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> over REZOLVE-AA trial disclosures\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pomerantz LLP said a securities class action has been filed against Nektar and certain officers in the U.S. District Court for the Northern District of California under docket 26-cv-01951. The suit seeks damages for investors who bought or acquired Nektar securities between Feb. 26, 2025 and Dec. 15, 2025, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The complaint alleges the company made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial. Nektar reported on Dec. 16, 2025 that the REZOLVE-AA trial missed statistical significance, citing four ineligible patients. Following that disclosure, the stock fell 8% to close at $49.16 on Dec. 16, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603121000PR_NEWS_USPR_____DC07181) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pomerantz files securities class action against Nektar Therapeutics over REZOLVE-AA trial disclosures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPomerantz files securities class action against Nektar Therapeutics over REZOLVE-AA trial disclosures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pomerantz files securities class action against Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> over REZOLVE-AA trial disclosures\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pomerantz LLP said a securities class action has been filed against Nektar and certain officers in the U.S. District Court for the Northern District of California under docket 26-cv-01951. The suit seeks damages for investors who bought or acquired Nektar securities between Feb. 26, 2025 and Dec. 15, 2025, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The complaint alleges the company made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial. Nektar reported on Dec. 16, 2025 that the REZOLVE-AA trial missed statistical significance, citing four ineligible patients. Following that disclosure, the stock fell 8% to close at $49.16 on Dec. 16, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603121000PR_NEWS_USPR_____DC07181) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL9rvqfr:1","article_id":"2618137403","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618137403","pubTimestamp":1773324069,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pomerantz LLP said a securities class action has been filed against Nektar and certain officers in the U.S. District Court for the Northern District of California under docket 26-cv-01951. The suit seeks damages for investors who bought or acquired Nektar securities between Feb. 26, 2025 and Dec. 15, 2025, alleging violations of Sections 10 and 20 of the Exchange Act and Rule 10b-5. The complaint alleges the company made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial. Nektar reported on Dec. 16, 2025 that the REZOLVE-AA trial missed statistical significance, citing four ineligible patients. Following that disclosure, the stock fell 8% to close at $49.16 on Dec. 16, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NKTR":"内克塔治疗"},"translate_title":"Pomerantz就REZOLVE-AA试验披露对Nektar Therapeutics提起证券集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":0.9},"content_text":"Pomerantz files securities class action against Nektar Therapeutics over REZOLVE-AA trial disclosures\n    \n\n        Pomerantz LLP said a securities class action has been filed against Nektar and certain officers in the U.S. District Court for the Northern District of California under docket 26-cv-01951. The suit seeks damages for investors who bought or acquired Nektar securities between Feb. 26, 2025 and Dec. 15, 2025, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The complaint alleges the company made misleading statements about enrollment compliance and protocol standards in its Phase 2b REZOLVE-AA trial. Nektar reported on Dec. 16, 2025 that the REZOLVE-AA trial missed statistical significance, citing four ineligible patients. Following that disclosure, the stock fell 8% to close at $49.16 on Dec. 16, 2025.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603121000PR_NEWS_USPR_____DC07181) on March 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618137403","isCrawlerRequest":true}